258 related articles for article (PubMed ID: 36170674)
1. Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1.
Tao Y; Remillard D; Vinogradova EV; Yokoyama M; Banchenko S; Schwefel D; Melillo B; Schreiber SL; Zhang X; Cravatt BF
J Am Chem Soc; 2022 Oct; 144(40):18688-18699. PubMed ID: 36170674
[TBL] [Abstract][Full Text] [Related]
2. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.
Schröder M; Renatus M; Liang X; Meili F; Zoller T; Ferrand S; Gauter F; Li X; Sigoillot F; Gleim S; Stachyra TM; Thomas JR; Begue D; Khoshouei M; Lefeuvre P; Andraos-Rey R; Chung B; Ma R; Pinch B; Hofmann A; Schirle M; Schmiedeberg N; Imbach P; Gorses D; Calkins K; Bauer-Probst B; Maschlej M; Niederst M; Maher R; Henault M; Alford J; Ahrne E; Tordella L; Hollingworth G; Thomä NH; Vulpetti A; Radimerski T; Holzer P; Carbonneau S; Thoma CR
Nat Commun; 2024 Jan; 15(1):275. PubMed ID: 38177131
[TBL] [Abstract][Full Text] [Related]
3. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
4. DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.
Zhang X; Luukkonen LM; Eissler CL; Crowley VM; Yamashita Y; Schafroth MA; Kikuchi S; Weinstein DS; Symons KT; Nordin BE; Rodriguez JL; Wucherpfennig TG; Bauer LG; Dix MM; Stamos D; Kinsella TM; Simon GM; Baltgalvis KA; Cravatt BF
J Am Chem Soc; 2021 Apr; 143(13):5141-5149. PubMed ID: 33783207
[TBL] [Abstract][Full Text] [Related]
5. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.
Zhang X; Crowley VM; Wucherpfennig TG; Dix MM; Cravatt BF
Nat Chem Biol; 2019 Jul; 15(7):737-746. PubMed ID: 31209349
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.
Wang C; Zhang Y; Zhang T; Shi L; Geng Z; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1667-1693. PubMed ID: 35702041
[TBL] [Abstract][Full Text] [Related]
7. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Nanomolar DCAF1 Small Molecule Ligands.
Li ASM; Kimani S; Wilson B; Noureldin M; González-Álvarez H; Mamai A; Hoffer L; Guilinger JP; Zhang Y; von Rechenberg M; Disch JS; Mulhern CJ; Slakman BL; Cuozzo JW; Dong A; Poda G; Mohammed M; Saraon P; Mittal M; Modh P; Rathod V; Patel B; Ackloo S; Santhakumar V; Szewczyk MM; Barsyte-Lovejoy D; Arrowsmith CH; Marcellus R; Guié MA; Keefe AD; Brown PJ; Halabelian L; Al-Awar R; Vedadi M
J Med Chem; 2023 Apr; 66(7):5041-5060. PubMed ID: 36948210
[TBL] [Abstract][Full Text] [Related]
9. Application of AlphaFold models in evaluating ligandable cysteines across E3 ligases.
Koldenhof P; Bemelmans MP; Ghosh B; Damm-Ganamet KL; van Vlijmen HWT; Pande V
Proteins; 2024 Jul; 92(7):819-829. PubMed ID: 38337153
[TBL] [Abstract][Full Text] [Related]
10. Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.
Mi D; Li Y; Gu H; Li Y; Chen Y
Eur J Med Chem; 2023 Aug; 256():115444. PubMed ID: 37178483
[TBL] [Abstract][Full Text] [Related]
11. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
Guenette RG; Potts PR
Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
[TBL] [Abstract][Full Text] [Related]
12. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
13. HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*.
Schiedel M; Lehotzky A; Szunyogh S; Oláh J; Hammelmann S; Wössner N; Robaa D; Einsle O; Sippl W; Ovádi J; Jung M
Chembiochem; 2020 Dec; 21(23):3371-3376. PubMed ID: 32672888
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis-targeting chimeras for targeting protein for degradation.
Qi J; Zhang G
Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
[TBL] [Abstract][Full Text] [Related]
15. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
17. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Vpx-Mediated SAMHD1 and Vpr-Mediated Host Helicase Transcription Factor Degradation by Selective Disruption of Viral CRL4 (DCAF1) E3 Ubiquitin Ligase Assembly.
Wang H; Guo H; Su J; Rui Y; Zheng W; Gao W; Zhang W; Li Z; Liu G; Markham RB; Wei W; Yu XF
J Virol; 2017 May; 91(9):. PubMed ID: 28202763
[TBL] [Abstract][Full Text] [Related]
19. Targeted Protein Degradation through E2 Recruitment.
Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
[TBL] [Abstract][Full Text] [Related]
20. Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios.
Verano AL; You I; Donovan KA; Mageed N; Yue H; Nowak RP; Fischer ES; Wang ES; Gray NS
ACS Chem Biol; 2022 Sep; 17(9):2404-2410. PubMed ID: 36007246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
